By lowering hepatic and plasma lipid levels, reducing inflammation, and enhancing insulin sensitivity, activation of the FXR may be able to reduce the symptoms of NAFLD [23]. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.